Connect with us

News

Wegovy works. But here’s what happens if you can’t afford to keep taking the drug

Published

on

Wegovy works. But here’s what happens if you can’t afford to keep taking the drug

Wegovy has been referred to as “a significant breakthrough” given how effectively it really works to scale back physique weight. However the injection drug is extraordinarily costly and when individuals cannot afford to remain on it, they expertise rebound weight acquire that is onerous to cease.

Katherine Streeter for NPR


disguise caption

toggle caption

Advertisement

Katherine Streeter for NPR


Wegovy has been referred to as “a significant breakthrough” given how effectively it really works to scale back physique weight. However the injection drug is extraordinarily costly and when individuals cannot afford to remain on it, they expertise rebound weight acquire that is onerous to cease.

Katherine Streeter for NPR

From TikTok influencers speaking it as much as celebrities worrying about “ozempic face,” medication like Wegovy and Ozempic are being touted as weight reduction miracles in a rustic obsessive about slimness.

However, the medication aren’t meant for beauty weight reduction. Ozempic is permitted for diabetes, and Wegovy is for individuals with weight problems who even have weight-related circumstances equivalent to hypertension or excessive ldl cholesterol that put them prone to coronary heart illness. That is hundreds of thousands of Individuals.

Advertisement

And proof reveals the brand new class of medication are far simpler than prior weight problems medicines. A landmark scientific trial revealed in The New England Journal of Drugs in 2021 discovered that the drug led to a 15% discount in physique weight, on common.

There’s been such a rise in demand that an FDA database lists the treatment’s energetic ingredient, semaglutide, as “at present in scarcity.” Its producer, Novo Nordisk, says maintaining provides secure is a precedence. The corporate additionally markets Ozempic to deal with diabetes, which is a decrease dose of semaglutide.

However at a value of about $1,400 a month — out of pocket when insurance coverage does not cowl it — many individuals cannot afford to remain on the treatment for the long run. And when individuals cease taking it, there’s typically rebound weight acquire that is onerous to manage. Actually, a examine discovered that most individuals acquire again many of the weight inside a yr of stopping the medication.

That is what is occurring to Yolanda Hamilton from South Holland, Ailing. Hamilton’s physician prescribed Wegovy as a result of she had an elevated BMI, hypertension and elevated blood sugar. She misplaced 60 kilos and began feeling a lot better.

“It gave me extra power,” she says, permitting her to train and do home chores. Her cravings for sugar subsided, and she or he felt happy from smaller meals. “I used to be very stunned by how good I felt,” Hamilton says. The drug is run by a as soon as per week injection at residence, which Hamilton says is simple to do.

Advertisement

Her Aetna insurance coverage plan lined the price of the treatment, however when she modified jobs final fall, her new insurance coverage plan by way of Blue Cross and Blue Protect of Illinois denied protection. She now works in a hospital ER registering sufferers, which requires her to sit down many of the day. And, after a number of months of not taking the drug, she has gained again 20 kilos.

“I am very annoyed in regards to the weight coming again on in so little time,” Hamilton says.

Blue Cross and Blue Protect of Illinois informed NPR that advantages provided by employer plans can fluctuate. “Weight-loss medication like Wegovy could also be lined, relying on the member’s profit plan,” a spokesperson for the corporate stated. Many different insurance coverage carriers additionally decide protection primarily based on what employers are keen to cowl.

Limitations to a life-changing drug

The rebound weight acquire just isn’t a shock given how the treatment works. Wegovy’s energetic ingredient — semaglutide — is a GLP-1, or glucagon-like peptide-1, which mimics the GLP-1 satiety hormone in our our bodies. Once we eat, GLP-1 is launched from our intestines and sends indicators to our mind facilities that management urge for food.

“This hormone is telling your mind, I am full, I needn’t eat anymore,” explains Dr. Robert Kushner of Northwestern College, who treats Yolanda Hamilton. Kushner additionally serves on a Novo Nordisk medical advisory board, for which he receives an honoraria.

Advertisement

“What the pharmaceutical firms have performed is taken this hormone that’s naturally occurring and restructured it right into a drug,” he explains. So, it is not a shock that when individuals cease taking the medication, they begin to really feel hungrier, he says.

“I crave sweets,” Hamilton says. And her urge for food has elevated. She not feels happy with small meals. “I am dropping my power” as the load comes again, she says.

Kushner’s workplace helps Hamilton attraction the insurance coverage denial, however as she waits, she’s frightened that stopping the treatment may even affect her blood stress and blood sugar. “She is prone to having these circumstances worsen with regain of weight,” Kushner says.

“If I acquire extra weight, I shall be on extra medicines,” says Hamilton. Given her lengthy wrestle with weight reduction, she’d lastly discovered one thing that was working.

“We’re seeing plenty of sufferers have this rebound weight acquire, and it will probably actually be devastating,” says Dr. Karla Robinson, a household doctor primarily based in Charlotte, N.C., and a medical editor at GoodRx, an organization that helps individuals discover the bottom costs for generic and model medication. There isn’t any generic model of semaglutide.

Advertisement

“Sadly, being a brand new treatment, it is a kind of that’s topic to the pricing of the producer,” Robinson says.

A consultant from Novo Nordisk notes that the corporate provides a $500 coupon for Wegovy to scale back the price for sufferers paying money.

However, this chart from GoodRX reveals the bottom worth amongst all retailers is $1,304 monthly for individuals paying out of pocket, which is out of attain for most individuals — even with a coupon.

“I do really feel like Wegovy is revolutionary,” Hamilton says. However she says she undoubtedly cannot afford to pay for it.

“A few of the individuals who want it probably the most are unable to entry it,” Robinson says, declaring that individuals with low incomes expertise weight problems at disproportionately larger charges.

Advertisement

“We’re speaking about an enormous well being fairness challenge,” she says. Black and Hispanic adults have larger charges of weight problems, in accordance with the CDC.

Since Wegovy was permitted by the FDA in 2021, some insurance coverage have begun to cowl the treatment for individuals who meet the scientific prescribing pointers. In line with the FDA, individuals are eligible if they’ve a BMI of 27 or larger and in addition have a minimum of one “weight-related ailment” equivalent to hypertension, diabetes, or excessive ldl cholesterol. Or they’ve a BMI of 30 or larger, no matter weight-related illnesses.

However insurance coverage protection could be very spotty. Medicare doesn’t cowl Wegovy or different weight reduction medication, and lots of insurers observe Medicare’s lead. More and more, there’s stress to alter this. As STAT reported final week, the Moffitt Most cancers Middle in Florida is lobbying for laws that may permit Medicare to pay for weight problems medication, citing the hyperlink between weight problems and most cancers threat. The NAACP can also be registered to foyer on this challenge.

As well as, the American Academy of Pediatrics has new steering recommending that pediatricians provide weight reduction medication to adolescents 12 and older with weight problems as an adjunct to habits change and life-style interventions.

Lengthy-term unknowns

However the truth that individuals might have to remain on Wegovy indefinitely with the intention to preserve the load loss has raised issues about long-term use. The commonest unwanted effects of the drug are GI signs. “Nausea, diarrhea, constipation, vomiting in some individuals, or heartburn,” Kushner says.

Advertisement

He says beginning with a low dose and growing it over time may also help individuals tolerate the drug higher. There’s ongoing analysis to guage the drug’s impact on the cardiovascular system, which is constructive to this point.

However the drug does carry a black field warning as a result of in rodent research it induced thyroid tumors. So, Kushner says medical doctors have to display screen sufferers to search out out if they’ve a household historical past of a selected sort of thyroid carcinoma, or one other uncommon situation referred to as a number of endocrine neoplasia syndrome kind 2 (MEN 2). “This could be a person affected person dialog,” Kushner says. Usually, if you do not have a historical past of those circumstances, “this treatment is considered secure,” he says.

If this sounds unsettling, it is a reminder of how excessive the stakes are to fight weight problems. The theoretical threat of thyroid tumors could also be unnerving. However medical doctors level to the dangers of leaving weight problems untreated: Coronary heart illness is the main reason behind dying within the U.S., and weight problems and weight-related circumstances are prime threat components.

In fact, train and weight-reduction plan modification are nonetheless the primary methods to strive. However on condition that about 70% of Individuals are chubby or overweight, almost half of adults within the U.S. have hypertension and greater than 1 in 3 have pre-diabetes, medical doctors’ teams cite an pressing have to layer on extra interventions that may be useful.

“We, as a society, are spending $173 billion in obesity-related well being care prices,” says Dr. Marcus Schabacker, CEO of ECRI, an unbiased, nonprofit group that has reviewed the proof of latest weight reduction medication.

Advertisement

He argues that the medication could be a part of destigmatizing weight problems by treating it like another illness that you simply deal with with drugs. “We might not ask somebody who has hypertension to only do workout routines and alter your weight-reduction plan after which you may be effective. No, we give them beta blockers. It is not totally different right here. Train and weight-reduction plan are key parts of tackling weight problems, however so are medicines which have confirmed to be efficient,” he says.

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

News

Yen tumbles after Bank of Japan holds near-zero interest rates

Published

on

Yen tumbles after Bank of Japan holds near-zero interest rates

Unlock the Editor’s Digest for free

The yen fell to a new 34-year low on Friday after the Bank of Japan stuck to its dovish tone, holding interest rates near zero despite rising pressure on the central bank to tighten its policy and prop up the ailing currency.

The Japanese currency fell to ¥156.71 against the dollar after the BoJ unanimously agreed to continue guiding its overnight interest rate within a range of about zero to 0.1 per cent.

In March, the central bank ended its negative interest rate policy, raising borrowing costs for the first time since 2007.

Advertisement

In the wake of its historic shift away from ultra-loose monetary policy, governor Kazuo Ueda indicated he would like to move gradually to raise rates.

But his position has been complicated by the yen’s depreciation and signals that the US Federal Reserve will keep interest rates high to tame inflation.

Investors had not expected the BoJ to change its policy this week, with the focus on whether Ueda would strike a hawkish tone regarding future rate rises to slow the yen’s decline.

Instead, Ueda said at a news conference on Friday that the central bank’s board members judged there was “no major impact” from the weaker yen on underlying inflation for now.

“Currency rates is not a target of monetary policy to directly control,” he said. “But currency volatility could be an important factor in impacting the economy and prices. If the impact on underlying inflation becomes too big to ignore, it may be a reason to adjust monetary policy.”

Advertisement

The yen held steady at about ¥155.55 a dollar in morning trading but weakened sharply within 10 minutes of the BoJ’s announcement as traders resumed bets that the US-Japan rate differential would continue to apply downward pressure on the Japanese currency.

The Nikkei 225 stock index briefly rose more than 1 per cent after the announcement. It closed up 0.8 per cent on Friday.

The BoJ forecast “core-core” inflation, a closely watched measure that strips out volatile food and energy prices, would remain near its 2 per cent target for the next three years. Ueda added that the central bank would raise rates or adjust the degree of its easing measures if prices rose in line with its outlook.

In a single-page statement, the BoJ also noted that it would continue to purchase Japanese government bonds in line with its March decision but dropped a previous footnote on how much it would buy each month.

“There is no intention by the BoJ to stop the yen’s decline, at least looking at its statement and its outlook report,” said UBS economist Masamichi Adachi. “The finance ministry will have to act [to stem the yen weakness].

Advertisement

“It would have been more effective if both the government and the BoJ faced the same direction,” he added.

The BoJ has long struggled to maintain price rises at sustainable levels to keep the economy out of deflation. While domestic consumption remains weak, the falling yen is expected to fuel inflation in the months ahead by increasing the cost of imported goods.

Investors expect the BoJ to raise rates in July at the earliest if the bank confirms increases in service inflation and real wages, which would help boost consumption. Following the dovish tone on Friday, however, Adachi said he does not expect the next rate rise until October.

“Markets remain on high alert for any indication of whether the yen’s current weakness will be interpreted as a lasting inflationary signal,” said Naomi Fink, global strategist at Nikko Asset Management.

“The BoJ however is likelier to find any knock-on impact from yen weakness upon inflation as more concerning than short-term currency moves.”

Advertisement
Continue Reading

News

CNN anchor presses Trump lawyer on Kagan military coup questioning

Published

on

CNN anchor presses Trump lawyer on Kagan military coup questioning

CNN anchor Kaitlan Collins pressed an attorney for former President Trump on a line of questioning by Supreme Court Justice Elena Kagan in the former president’s presidential immunity case at the Supreme Court Thursday.

“What are the circumstances where ordering a military coup is an official act of the presidency?” Collins said, referring to a back-and-forth between Kagan and Trump lawyer D. John Sauer in which she questioned him on presidential immunity in the case of a president ordering the military to stage a coup.

“When you’re talking about official acts, you don’t look to intent, you don’t look to purpose, you look to their underlying character,” Scharf responded. “So if that were — if that sort of situation were to unfold using the official powers of the president, you could see there being an aspect of officialness to that.”

The two went back and forth, and Collins later remarked that Sharf was making “a pretty brazen argument, that military coups could potentially be official acts.”

Sharf retorted that the argument is not meant to justify such things, but to define the scope of immunity presidents have been acting in office.

Advertisement

“Just because a military coup or any of these sort of parade of horribles could constitute an official act doesn’t mean that they’re right, doesn’t mean that they would be allowed under a constitutional system and doesn’t mean that we’re in any way shape or form justifying that,” he said. “What we’re talking about here, though, is the scope of immunity that presidents need to be able to rely on to discharge their core article to responsibilities as president.”

When asked about if a president ordering “the military to stage a coup” is an “official act” by Kagan on Thursday as the Supreme Court held a hearing on Trump’s claims of immunity, Sauer responded that “it could well be.”

On the same day of the Supreme Court hearing, the former president was in court in New York for his hush money case, which began last week. The case marks the first criminal trial of a former American president. He has been charged with 34 counts of falsifying business records in relation to reimbursements to his attorney at the time, Michael Cohen, who paid an adult film actor $130,000 prior to the 2016 election to keep quiet about an alleged affair with Trump, which he denies.

Copyright 2024 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Advertisement
Continue Reading

News

South Korea warns Joe Biden’s EV subsidy scheme at risk of ‘collapse’

Published

on

South Korea warns Joe Biden’s EV subsidy scheme at risk of ‘collapse’

Unlock the Editor’s Digest for free

China’s control over a crucial battery material will make it nearly impossible for any electric-vehicle makers to qualify for the subsidy scheme at the heart of President Joe Biden’s flagship green tech legislation, South Korea has warned.

Biden’s Inflation Reduction Act seeks to eliminate “foreign entities of concern” — which include companies with close ties to Beijing — from the US EV supply chain, with restrictions due to come into force on January 1 2025.

But Chinese companies control more than 99 per of the global market for battery-grade graphite and 69 per cent of the market for synthetic graphite used in battery anodes, according to consultancy Benchmark Minerals Intelligence.

Advertisement

Without an exemption to the FEOC rules for battery makers to secure graphite from Chinese suppliers, it is possible that no vehicles will qualify for the generous tax credits that the Biden administration is offering EV buyers, Ahn Duk-geun, South Korea’s minister of trade, industry and energy, has warned.

“Unless they make some kind of exemption or transition period, the whole [EV subsidy] regime will collapse,” Ahn told the Financial Times, adding that Seoul had raised the issue with the US commerce department. “I believe they will try to find a way to somehow take this market reality into consideration.”

South Korean companies have already committed to investing tens of billions of dollars in advanced technology facilities in the US in order to take advantage of expansive subsidies for semiconductor and battery manufacturing.

The US announced last week that it would offer up to $6.4bn in federal subsidies to South Korean tech giant Samsung Electronics, which is investing $40bn in its Texas facilities for cutting-edge logic chips, advanced packaging and research and development on next-generation chip technologies. SK Hynix, a maker of memory chips, is building an advanced packaging facility in Indiana.

South Korean battery makers LG Energy Solution, SK On and Samsung SDI, which have all received billions of dollars under the IRA, are projected to account for 44 per cent of North America’s total battery capacity by 2030, according to Benchmark.

Advertisement

But he noted that future US administrations could cause “huge trouble” for South Korean companies by modifying or repealing elements of the IRA, which Republican presidential candidate Donald Trump has threatened to gut in favour of increased fossil fuel investment. Beijing also introduced controls on graphite exports last year.

The Korea Semiconductor Industry Association has expressed concern that South Korean chipmakers’ large investments in the US could jeopardise the country’s competitive edge, with its executive director Ahn Ki-hyun telling the FT this month: “We could lose our status as a chipmaking powerhouse if our companies continue to build plants abroad.”

But Ahn, the trade minister, said extra capacity outside South Korea was required to meet booming future demand for artificial intelligence-related hardware.

“The one major difference of Korean industry from China, the US or Japan is that we have a small population and a small territory,” he said. “So we cannot produce everything here, and some of our companies need to go [overseas] to major markets. We encourage them to do that.”

The trade minister conceded that Seoul would need to offer better incentives for chipmakers to continue building more capacity in South Korea, as other countries — including the US — pursue “nationalistic industrial policies”. South Korea’s conservative president, Yoon Suk Yeol, declared last year that the country was engaged in an “all-out”, global “semiconductor war.”

Advertisement

But minister Ahn added that the reorientation of supply chains amid intensifying US-China tensions would benefit South Korea’s traditional strength of trade diversification, as other countries seek to reduce their dependence on China and Taiwan.

“When they try to ‘de-risk’ from any particular country, they are going to need new partners,” said Ahn. “We are a perfect partner for countries that are trying to build their own fortress — that is our survival strategy.”

Video: How Biden’s Inflation Reduction Act changed the world | FT Film
Continue Reading

Trending